CLINICAL TRIALS PROFILE FOR ANAVEX2-73
✉ Email this page to a colleague
Clinical Trials for ANAVEX2-73
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02244541 ↗ | Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease | Completed | Anavex Life Sciences Corp. | Phase 2 | The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship between dosing regimen and pharmacodynamics efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore the relationship of ANAVEX2-73 as add-on therapy to AD standard of care. |
| NCT02756858 ↗ | An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease | Completed | Anavex Life Sciences Corp. | Phase 2 | This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002. |
| NCT03758924 ↗ | Study of ANAVEX2-73 in Patients With Rett Syndrome | Completed | International Rett Syndrome Foundation Rettsyndrome.org | Phase 2 | Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension. |
| NCT03758924 ↗ | Study of ANAVEX2-73 in Patients With Rett Syndrome | Completed | Anavex Life Sciences Corp. | Phase 2 | Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension. |
| NCT03774459 ↗ | ANAVEX2-73 Study in Parkinson's Disease Dementia | Completed | Anavex Germany GmbH | Phase 2 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD) |
| NCT03774459 ↗ | ANAVEX2-73 Study in Parkinson's Disease Dementia | Completed | Anavex Life Sciences Corp. | Phase 2 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD) |
| NCT03790709 ↗ | ANAVEX2-73 for Treatment of Early Alzheimer's Disease | Active, not recruiting | Anavex Australia Pty Ltd. | Phase 2/Phase 3 | Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for ANAVEX2-73
Condition Name
Clinical Trial Locations for ANAVEX2-73
Trials by Country
Clinical Trial Progress for ANAVEX2-73
Clinical Trial Phase
Clinical Trial Sponsors for ANAVEX2-73
Sponsor Name
